预计到 2030 年，胰腺癌 (PDAC) 将成为癌症死亡的第二大原因，这主要是由于治疗失败。有限的治疗选择和对标准护理 (SoC) 疗法的抵抗使得 PDAC 成为预后和生存率最差的癌症类型之一 [1,2]。胰腺肿瘤因对靶向治疗、化疗和放疗等治疗干预反应不佳而闻名。在此，我们回顾了 PDAC 治疗抵抗的标志以及当前旨在解决逃逸机制并使胰腺细胞对治疗重新敏感的策略。我们将进一步提供有关药物发现、纳米医学和疾病模型领域最新进展的见解，这些进展为未来的研究奠定了基础。版权所有 © 2024 作者。由爱思唯尔公司出版。保留所有权利。

Pancreatic adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer deaths by 2030 and this is mostly due to therapy failure. Limited treatment options and resistance to standard-of-care (SoC) therapies makes PDAC one of the cancer types with poorest prognosis and survival rates [1,2]. Pancreatic tumors are renowned for their poor response to therapeutic interventions including targeted therapies, chemotherapy and radiotherapy. Herein, we review hallmarks of therapy resistance in PDAC and current strategies aiming to tackle escape mechanisms and to re-sensitize pancreatic cells to therapy. We will further provide insights on recent advances in the field of drug discovery, nanomedicine, and disease models that are setting the ground for future research.Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.